Not available
Quote | Arcus Biosciences Inc. (NYSE:RCUS)
Last: | $18.88 |
---|---|
Change Percent: | -0.49% |
Open: | $18.3 |
Close: | $18.88 |
High: | $19.11 |
Low: | $18.18 |
Volume: | 741,416 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Arcus Biosciences Inc. (NYSE:RCUS)
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Lee...
2024-02-21 17:57:25 ET More on Arcus Biosciences Arcus Biosciences: Showing There Might Be Something To TIGIT After All Arcus Biosciences: Did Gilead Sciences overpay for its latest investment? Arcus shares extend gains amid mixed reactions on Gilead stake purchase ...
Message Board Posts | Arcus Biosciences Inc. (NYSE:RCUS)
Subject | By | Source | When |
---|---|---|---|
Biotechs are starting to react to news...finally. | conix | investorshub | 04/05/2022 3:26:51 PM |
The stock didn't react as well as expected | dinogreeves | investorshub | 05/27/2020 12:46:59 PM |
Also in the DEF 14.....didnt see any information | lovetc | investorshub | 04/22/2020 2:48:12 AM |
shorted some and bought some put at $31 | lovetc | investorshub | 04/22/2020 2:46:30 AM |
RCUS will likely hit 40 this week and | dinogreeves | investorshub | 04/21/2020 1:25:35 AM |
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Lee...
Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical needs and largest market opportunities Pharmacokinetic (PK), pharmacodynamic (PD), safety and...
Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...